HIV阳性受试者对皮内注射重组乙型肝炎疫苗的抗体反应。

Antibody responses to intradermal recombinant hepatitis B immunization among HIV-positive subjects.

作者信息

Ristola Matti A, Vuola Jenni M, Valle Martti, von Reyn C Fordham

机构信息

Department of Medicine, Division of Infectious Diseases, Helsinki University Central Hospital, PO Box 348, FIN-00029 HUS Helsinki, Finland.

出版信息

Vaccine. 2004 Nov 25;23(2):205-9. doi: 10.1016/j.vaccine.2004.05.010.

DOI:10.1016/j.vaccine.2004.05.010

PMID:15531038

Abstract

We conducted a randomized, controlled clinical trial to determine the immunogenicity of intradermal immunization with recombinant hepatitis B vaccine among HIV-positive subjects. Induction of antibody concentration over 10 IU/L or four-fold increase in the antibody concentration against hepatitis B surface antigen was regarded a successful immunization. Intradermal immunization induced protective immunity in 39% of participants who received three doses of recombinant hepatitis B vaccine. Intradermal immunization may provide a way to improve the outcome of hepatitis B vaccination among HIV-infected persons. Three doses of intradermal immunization alone induces protective immunity against hepatitis B as often as intramuscular immunization.

摘要

我们开展了一项随机对照临床试验，以确定重组乙型肝炎疫苗皮内免疫在HIV阳性受试者中的免疫原性。抗乙型肝炎表面抗原抗体浓度诱导超过10 IU/L或抗体浓度增加四倍被视为免疫成功。皮内免疫在39%接受三剂重组乙型肝炎疫苗的参与者中诱导了保护性免疫。皮内免疫可能为改善HIV感染者乙型肝炎疫苗接种效果提供一种方法。仅三剂皮内免疫诱导乙型肝炎保护性免疫的频率与肌肉注射相同。